AVITI Alliance Biomodal's duet multiomics solutions now integrate with Element Biosciences AVITI platforms, enabling a direct cross sell to AVITI instrument users seeking coordinated genetic and epigenetic profiling from low input samples.

Epigenetic Advantage A new epigenetic sequencing sample prep assay differentiates unmodified, methylated, and hydroxymethylated cytosines, creating a compelling offer for cancer, neurodegenerative disease, and ageing research teams.

Growth Credibility The Sunday Times Tech 2026 recognition signals fast growth and market credibility, helping to open conversations with UK biotech startups, CROs, and academic labs seeking scalable omics analytics partners.

Regional Access Based in Little Chesterford near Cambridge, biomodal can leverage the regional biotech ecosystem to secure pilots, collaborations, and sponsored research with universities and local biotech clusters.

Diverse Market Fit With applications across cancer, ageing, and neurodegenerative research, biomodal can expand sales into pharma R&D, biotech discovery, and diagnostics by offering end to end omics analytics and data workflows.